Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

Purpose

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).

Condition

  • Interstitial Lung Diseases

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Outpatients of either gender, age greater than or equal to 18 years 2. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.) 3. Subject has no diagnosed pulmonary conditions 4. Subject has not smoked in the previous 5 years 5. Smoking history, if any, is less than or equal to 5 pack-years 6. No history of using other inhaled products more than 1 time per week for > 1 year

Exclusion Criteria

Subjects presenting with any of the following will not be included in the trial: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionnaire 3. Subject is pregnant or lactating 4. Resting oxygen saturation on room air <90% 5. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 6. Subject has history of any known ventricular cardiac arrhythmia 7. Subject has history of cardiac arrest within the last year 8. Subject does not fit into Xe vest coil used for MRI 129 9. Subject cannot hold his/her breath for 15 seconds 10. Subject deemed unlikely to be able to comply with instructions during imaging 11. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial: 1. Outpatients of either gender, age greater than or equal to 18 years 2. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.) 3. Clinical diagnosis of Interstitial Lung Disease made by a board certified pulmonologist using established criteria. We will not exclude individuals based on ILD type or severity of disease with the exception of the below criteria Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial: 1. Subject is less than 18 years old 2. MRI is contraindicated based on responses to MRI screening questionnaire 3. Subject is pregnant or lactating 4. Resting oxygen saturation <90% on supplemental oxygen 5. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 6. Subject has history of any known ventricular cardiac arrhythmia. 7. Subject has history of cardiac arrest within the last year 8. Subject does not fit into Xe vest coil used for MRI 129 9. Subject cannot hold his/her breath for 15 seconds 10. Subject deemed unlikely to be able to comply with instructions during imaging 11. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Patients with Interstitial Lung Disease
  • Drug: Hyperpolarized 129Xe
    Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.
Active Comparator
Healthy Volunteers
  • Drug: Hyperpolarized 129Xe
    Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.

Recruiting Locations

University of Iowa
Iowa City, Iowa 52242
Contact:
Sean Fain
319-356-4832
Sean-fain@uiowa.edu

Duke University Medical Center
Durham, North Carolina 27710
Contact:
Jennifer Korzekwinski
919-681-7362
jennifer.korzekwinski@duke.edu

University of Cincinnati
Cincinnati, Ohio 45219
Contact:
Nishant Gupta
513-558-4831
guptans@ucmail.uc.edu

Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
Contact:
Zackary Cleveland
513-803-7186
zackary.cleveland@cchmc.org

More Details

NCT ID
NCT04855305
Status
Recruiting
Sponsor
Bastiaan Driehuys

Study Contact

Bastiaan Driehuys, PhD
919-684-7786
bastiaan.driehuys@duke.edu